January 24, 2020 - 9:00am

Department of State Health Services, Robert D. Moreton Building, Public Hearing Room, M-100
1100 West 49th St.
Austin, TX 78756

Add to My Calendar

Webcasting Available

This meeting will be webcast. To access the webcast, go to https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings the day and time of the meeting.

  1. Call to order
  2. Approval of minutes from October 25, 2019 (vote required)
  3. Texas Insurance Code chapter 1360, subchapter E-1, as adopted by HB 1584, 86th Leg., R.S. (2019) update – coverage of prescription drugs for stage four advanced, metastatic cancer and associated conditions
  4. New business:
    Public comment on drug classes to be reviewed for the Medicaid preferred drug list (PDL):
    1. Acne agents, oral
    2. Acne agents, topical
    3. Analgesics, narcotics long
    4. Analgesics, narcotics short
    5. Angiotensin modulator combinations
    6. Angiotensin modulators
    7. Antimigraine agents, other
    8. Antimigraine agents, triptans
    9. Bladder relaxant preparations
    10. Glucagon agents
    11. H. Pylori treatment
    12. Immunomodulators, atopic dermatitis
    13. Intranasal rhinitis agents
    14. Movement disorders
    15. Neuropathic pain
    16. Phosphate binders
    17. Platelet aggregation inhibitors
    18. Progestins for cachexia
    19. Proton pump inhibitors
    20. Smoking cessation
    21. Stimulants and related agents
  5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:
    1. Nourianz (oral) / Antiparkinson's agents
    2. Proair Digihaler (inhalation) / Bronchodilators, beta agonist
    3. Duaklir Pressair (inhalation) / chronic obstructive pulmonary disease agents
    4. Rybelsus (oral) / Hypoglycemics, incretin mimetics/enhancers
    5. Fiasp Penfill (subcutaneous) / Hypoglycemics, insulin and related agents
    6. Xembify (subcutaneous) / immune globulins
    7. Relafen DS (oral) / nonsteroidal anti-inflammatory drugs
  6. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
  7. Executive work session
    Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
  8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
  9. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Fentanyl (inhalation/oral transdermal)
    2. Gabapentin
    3. Hydrocodone Bitrate/Hydrocodone Polistirex
    4. Ivacaftor (Kalydeco®) and Combination Therapy
    5. Topical Calcineurin Inhibitors- Pimecrolimus (Elidel®), Tacrolimus (Protopic®)
    6. Tramadol (Ultram®)
  10. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR interventions:
      1. Anticonvulsant drug use evaluation
      2. Influenza prevention
      3. Cough and cold remedies
    2. Report on recent retrospective DUR intervention outcomes:
      1. Second generation antipsychotics in youth
      2. Proton pump inhibitors
      3. Appropriate use of antibiotics
    3. Retrospective DUR proposals (vote required)
      1. Diabetes disease management
      2. Monitoring of psychotropic drugs in youth
      3. Postpartum depression
  11. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Cystic Fibrosis Agents – additional of Trikafta™ criteria
    2. Inhaled antibiotics – revision
    3. Oxbryta™ – new criteria
    4. Pulmonary arterial hypertension (PAH) agents – addition of oral PAH agents
  12. Next meeting date: April 24, 2020
  13. Adjourn

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/Formulary Support Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or VDP-Advisory@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 or VDP-Advisory@hhsc.state.tx.us at least 72 hours before the meeting so appropriate arrangements can be made.